Download TAG Mail 2 December 2015 The purpose of TAG Mail is to assist

TAG Mail 2 December 2015
The purpose of TAG Mail is to assist TAG members identify and share relevant information for their professional
practice. Members are encouraged to routinely forward TAG Mail to others who they believe would benefit
from this information such as colleagues in the same hospital department if they are not already receiving TAG
Mail.
TAG ACTIVITIES
**Meetings
- TAG General Meeting – 14 December 2015 - 3.00pm – St Vincent’s Hospital or via teleconference
- TAGNet Meeting – 15 December2015 - 11.00am - TAG Offices or via teleconference
**Sasha Bennett and Margaret Jordan attended the APSA-ASCEPT Joint Scientific Meeting in Hobart 29 Nov – 2
Dec 2015. NSW TAG had three presentations accepted:
“Hospital evaluation of medicine usage………past its DUE date?” (Poster)
“An analysis of prescribing and supply of medicines for ophthalmic surgery in NSW hospitals” (Poster)
“Optimising the logistics of life-saving drug procurement and supply in NSW and the ACT” (Oral presentation)
**Sasha Bennett, Andrew Hargreaves, Margaret Jordan and Christa Lynch will be attending Medicines
Management 2015, the 41st SHPA National Conference in Melbourne 3-6 December 2015. Andrew
Hargreaves will present:
“Mining Diamonds: Crystalising Safety & Quality standards for eHealth NSW’s flagship eMeds Program”
(Poster)
**Email discussions:
- IV phenytoin administration and use of filters; closes 3 December 2015
TAG WEBSITE
- Report: An analysis of prescribing and supply of medicines for ophthalmic surgery in NSW public hospitals –
2015
http://www.ciap.health.nsw.gov.au/nswtag/pages/project-reports.html
- Email discussion: ToujeoTM Insulin 300units/mL (members only)
http://www.ciap.health.nsw.gov.au/nswtag/pages/email-discussions.html
REPORTS AND PUBLICATIONS – AUSTRALIA
**AIHW
- The health of Australia’s prisoners 2015
http://www.aihw.gov.au/publication-detail/?id=60129553527
- Australia’s registered health professions workforce
http://www.aihw.gov.au/workforce-data/
**ACSHC
- Australian Atlas of Healthcare Variation
http://www.safetyandquality.gov.au/atlas/
**TGA
- Updates to the list of designated orphan drugs:
Alectinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung
cancer.
Sebelipase Alfa for the treatment of lysosomal acid lipase (LAL) deficiency
https://www.tga.gov.au/updates-list-designated-orphan-drugs
- AusPAR added : Apremilast (OtezlaR) approved for the treatment of signs and symptoms of active psoriatic
arthritis in adult patients, and the treatment of adult patients with moderate to severe plaque psoriasis who
are candidates for phototherapy or systemic therapy.
http://www.tga.gov.au/auspar/auspar-apremilast
- AusPAR added: Regorafenib (StivargaR) extension of indication approved, for the treatment of patients with
unresectable or metastatic gastrointestinal stromal tumours (GIST) who progressed on or are intolerant to
prior treatment with imatinib and sunitinib.
https://www.tga.gov.au/auspar/auspar-regorafenib-0
- AusPAR added: Certolizumab pegol (Cimzia R) extension of indication. Approved for rheumatoid arthritis
“Cimzia has been shown to reduce the rate of progression of joint damage as measured by X-ray, when given
in combination with MTX.”
https://www.tga.gov.au/auspar/auspar-certolizumab-pegol-rbe
- AusPAR added : Apixaban (Eliquis) extension of indication. Approved for the treatment of deep vein
thrombosis (DVT) and pulmonary embolism (PE) in adult patients and for the prevention of recurrent DVT and
PE in adult patients.
https://www.tga.gov.au/auspar/auspar-apixaban-1
- AusPAR added: Anakinra (Kineret) extension of indication. Approved for the treatment of active Systemic
Juvenile Idiopathic Arthritis (SJIA). Anakinra may be used alone or in combination with DMARDs’.
https://www.tga.gov.au/auspar/auspar-anakinra
- AusPAR added: Rifaximin (Xifaxan) extension of indication. Approved for the treatment of adult patients with
travellers’ diarrhoea caused by non-invasive enteric bacteria.
https://www.tga.gov.au/auspar/auspar-rifaximin-0
**NPS Medicinewise
- Atlas shines a light on healthcare variation
http://www.nps.org.au/media-centre/media-releases/repository/atlas-shines-a-light-on-healthcare-variation
- Medicinal cannabis: the evidence and the challenges
http://www.nps.org.au/media-centre/media-releases/repository/medicinal-cannabis-theevidence-and-thechallenges
- National Medicines Symposium 2016
http://www.nps.org.au/about-us/what-we-do/campaigns-events/national-medicines-symposium/nms-2016making-wise-decisions-about-medicines-tests-and-technologies
- NPS Direct - November 2015
http://www.nps.org.au/health-professionals/e-newsletters/nps-direct/2015/november
- NPS RADAR December 2015
http://www.nps.org.au/publications/health-professional/nps-radar/2015/december-2015
REPORTS AND PUBLICATIONS – INTERNATIONAL
**CADTH
- Treatment of Angiotensin Converting Enzyme Inhibitor-Induced Angioedema: Guidelines
https://www.cadth.ca/sites/default/files/pdf/htis/nov2015/RB0938%20Icatibant%20for%20Angioedema%20Fi
nal.pdf
- Bismuth Salts for Gastrointestinal Issues: A Review of the Clinical Effectiveness and Guidelines
https://www.cadth.ca/sites/default/files/pdf/htis/nov2015/RC0720%20Bismuth%20Subsalicylate%20Final.pdf
**FDA
- Necitumumab (PortrazzaR) approved to treat patients with advanced (metastatic) squamous non-small cell
lung cancer (in combination with two forms of chemotherapy) who have not previously received medication
specifically for treating their advanced lung cancer.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474131.htm
- FDA approves FluadR, the first seasonal influenza vaccine containing an adjuvant.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474295.htm
- Elotuzumab (EmplicitiR) approved to treat patients with multiple myeloma (in combination with two other
therapies) who have received one to three prior medications.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474684.htm
**EMA
- Risk minimisation strategy for high-strength and fixed-combination insulin products
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/11/
WC500196980.pdf
- Good practice guide on recording, coding, reporting and assessment of medication errors
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/11/
WC500196979.pdf
- Good practice guide on risk minimisation and prevention of medication errors
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/11/
WC500196981.pdf
**NICE
-- Guidance
- Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset
http://www.nice.org.uk/guidance/ng16
- Transition between inpatient hospital settings and community or care home settings for adults with social
care needs
http://www.nice.org.uk/guidance/ng27
MEDICATION SAFETY
**TGA
- Medicines Safety update volume 6 number 6 December 2015
https://www.tga.gov.au/publication-issue/medicines-safety-update-volume-6-number-6-december-2015
**GOV.UK
- Drug Safety Update – November 2015
https://www.gov.uk/government/publications/drug-safety-update-monthly-newsletter
PAPERS OF INTEREST
**Australian Journal of Primary Health
- Medication-taking behaviour in New South Wales patients with type 2 diabetes: an observational study
http://www.publish.csiro.au/nid/261/paper/PY14062.htm
**British Journal of Clinical Pharmacology
- Proton Pump Inhibitor Associated Hypomagnasaemia - A Cause for Concern?
http://onlinelibrary.wiley.com/doi/10.1111/bcp.12846/abstract
- Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in
patients with digestive cancer
http://onlinelibrary.wiley.com/doi/10.1111/bcp.12790/abstract
- Evidence for the changing regimens of acetylcysteine
http://onlinelibrary.wiley.com/doi/10.1111/bcp.12789/full
**BMJ
- Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane
systematic review with meta-analyses and trial sequential analyses of randomised clinical trials
http://www.bmj.com/content/351/bmj.h5203
**EJHP
- Optimal dosing of angiotensin-converting enzyme inhibitors and β-blockers for acute coronary syndrome: uptitration remains a challenge
http://ejhp.bmj.com/content/early/2015/11/27/ejhpharm-2015-000783.short?g=w_ejhp_ahead_tab
**JAMA
Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1
Diabetes: A Randomized Clinical Trial
http://jama.jamanetwork.com/article.aspx?articleid=2473492
**JAMIA
The impact of real-time alerting on appropriate prescribing in kidney disease: a cluster randomized controlled
trial
http://jamia.oxfordjournals.org/content/early/2015/11/27/jamia.ocv159
**Journal of Clinical Oncology
- Effect of Granulocyte-Macrophage Colony-Stimulating Factor on Prevention and Treatment of Invasive Fungal
Disease in Recipients of Allogeneic Stem-Cell Transplantation: A Prospective Multicenter Randomized Phase IV
Trial
http://jco.ascopubs.org/content/33/34/3999.abstract
**Journal for healthcare quality
Medication Discrepancies During Transitions of Care: A Comparison Study
http://journals.lww.com/jhqonline/Abstract/2015/11000/Medication_Discrepancies_During_Transitions_of.1.
aspx
**Clinics in Geriatric Medicine
Long-term Toxicity of Cancer Treatment in Older Patients
http://www.sciencedirect.com/science/article/pii/S0749069015000737
CONSULTATIONS
**TGA
- Proposed amendments to the poisons standard: Closes 10 December 2015
https://www.tga.gov.au/consultation-invitation/consultation-proposed-amendments-poisons-standard-acmsmeeting-march-2016
OTHER NEWS
Nil
UPCOMING EVENTS (new additions in bold)
**Uppsala Monitoring Centre (WHO Collaborating Centre for International Drug Monitoring) and JSS
University, Asia Pacific Pharmacovigilance Training Course, 18-29 January, 2016, Mysore, India
http://jsspharma.org/sites/default/files/downloads/Asia_Pacific_Pharmacovigilance.pdf
**EAHP
21st Congress of the EAHP (European Association of Hospital Pharmacists)
‘Hospital pharmacists taking the lead – partnerships and technologies’, 16-18 March 2016, Vienna, Austria
http://www.eahp.eu/congresses
**International Association of Risk Management in Medicine
“IARMM General Assembly 2016” jointly with "5th World Congress of Clinical Safety (5WCCS)", 21 - 23
September 2016, Harvard University Medical School Boston, USA
http://www.iarmm.org/5WCCS/(poster)5WCCS_2016.pdf
**EUFEPS
- European Federation for Pharmaceutical Sciences 2016 Meeting
“Clinical Outcome and Regulatory Approaches for Advanced Drug Delivery Products”, 13-15 June 2016,
Istanbul Turkey
www.eufepsannualmeeting.org
**IHI
- Breakthrough Series College, March 29–31, 2016 , Cambridge, MA, USA
http://www.ihi.org/education/InPersonTraining/BreakthroughSeriesCollege/March2016BTSCollege/Pages/def
ault.aspx?utm_campaign=BTSC+March+2016&utm_source=hs_email&utm_medium=email&utm_content=232
97166&_hsenc=p2ANqtz-8OZ9FlsGQcddH1o-ZNv6O1HroyFhMRkGGNJGguLz6tVMFNzzDnfEnD27lS_AvTGX8l9wNb0ItEXMdDxKH86r4Nb2f1A&_hsmi=23297166
- Patient Safety Executive Development Program
March 3-9, 2016 Cambridge, MA
http://www.ihi.org/education/InPersonTraining/PatientSafetyExecutive/PatientSafetyExecutiveDevelopment
March2016/Pages/default.aspx?utm_campaign=2016+March+PSO&utm_source=hs_email&utm_medium=em
ail&utm_content=23544167&_hsenc=p2ANqtz-93OUZyfrSpkxcCiEMBnZJ1H7xK3GHpQESS91qc89pkN1_5QGSKD6EGuewKQ4lmkVym2oaQKK029gb3_Gu-RRumC9EWw&_hsmi=23544167
**The Laboratory of Innovative Practices on Polypharmacy and Health
3rd International Short Film and Photography Festival, May 2016
The participants' short films and photos should cover one of the following issues:
- Primary health care understood as the essential health care accessible to all individuals and families in the
community by means acceptable to them, with their full participation and at an affordable cost to the
community.
-Safe, appropriate and prudent use of medicines understood as the absence of unnecessary actual or potential
harm associated with medicines use.
-Medicalization of life understood as the process by which events of everyday life are converted into health
problems; and from that perspective they are addressed and treated by different health professionals.
Entries close 30 April 2016
http://polimedicado.org
You are receiving this email because you or a workplace colleague has requested TAG Mail. NSW TAG analyses
uptake of TAG Mail (email openings and clicks on specific contents) in order to optimise the TAG Mail service
for our members and colleagues. By requesting TAG Mail, you are also agreeing to have your data (email
address, country of abode) captured. All information obtained is used in accordance with NSW Health Privacy
Policy. Please contact NSW TAG at [email protected] if you have any questions regarding this.